Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study

Abstract

Summary Background Typhoid fever is a major cause of morbidity and mortality in low-income and middle-income countries. In 2017, WHO recommended the programmatic use of typhoid Vi-conjugate vaccine (TCV) in endemic settings, and Gavi, The Vaccine Alliance, has pledged support for vaccine introduction in these countries. Country-level health economic evaluations are now needed to inform decision-making. Methods In this modelling study, we compared four strategies: no vaccination, routine immunisation at 9 months, and routine immunisation at 9 months with catch-up campaigns to either age 5 years or 15 years. For each of the 54 countries eligible for Gavi support, output from an age-structured transmission-dynamic model was combined with country-specific treatment and vaccine-related costs, treatment outcomes, and disability weights to estimate the reduction in typhoid burden, identify the strategy that maximised average net benefit (ie, the optimal strategy) across a range of country-specific willingness-to-pay (WTP) values, estimate and investigate the uncertainties surrounding our findings, and identify the epidemiological conditions under which vaccination is optimal. Findings The optimal strategy was either no vaccination or TCV immunisation including a catch-up campaign. Routine vaccination with a catch-up campaign to 15 years of age was optimal in 38 countries, assuming a WTP value of at least US$200 per disability-adjusted life-year (DALY) averted, or assuming a WTP value of at least 25% of each country's gross domestic product (GDP) per capita per DALY averted, at a vaccine price of $1·50 per dose (but excluding Gavi's contribution according to each country's transition phase). This vaccination strategy was also optimal in 48 countries assuming a WTP of at least $500 per DALY averted, in 51 with assumed WTP values of at least $1000, in 47 countries assuming a WTP value of at least 50% of GDP per capita per DALY averted, and in 49 assuming a minimum of 100%. Vaccination was likely to be cost-effective in countries with 300 or more typhoid cases per 100 000 person-years. Uncertainty about the probability of hospital admission (and typhoid incidence and mortality) had the greatest influence on the optimal strategy. Interpretation Countries should establish their own WTP threshold and consider routine TCV introduction, including a catch-up campaign when vaccination is optimal on the basis of this threshold. Obtaining improved estimates of the probability of hospital admission would be valuable whenever the optimal strategy is uncertain. Funding Bill & Melinda Gates Foundation, Research Foundation–Flanders, and the Belgian–American Education Foundation.

Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

“…These results provide strong evidence that TCV can play an important role in the control of typhoid fever in endemic settings. TCV is highly cost-effective in high transmission settings and should be taken into account in country decision-making 27 . However, further data are still required to demonstrate vaccine efficacy in the medium- and long-term, the indirect effect and herd immunity achieved from large-scale vaccination, and the effectiveness in different age groups and populations.…”

The Invisible Burden: Diagnosing and Combatting Typhoid Fever in Asia and Africa

“…Mathematical modeling was able to explain the observed epidemic based on surveillance data from QECH and predicted that the number of cases would decrease following the epidemic peak in 2013–2014 but stabilize at an endemic level that was approximately 10-fold higher than prior to the epidemic [59]. Unpublished data from the Strategic Typhoid Alliance across Africa and Asia has confirmed this ongoing high incidence of disease from a single urban township in Blantyre [60]. Meanwhile, additional typhoid outbreaks have been reported from numerous locations throughout the country, including 1 outbreak with uncharacteristically high levels of neurological sequalae [61].…”

A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations

“…In this article, threshold values were determined for an evaluation comparing only 2 health care strategies (vaccination strategy RC15 compared to the baseline option [no vac]) and for an evaluation comparing 3 health care strategies (vaccination strategies RC5 and RC15 v. the baseline option [no vac]), since routine vaccination without catchup was never the optimal strategy in the original analysis. 8 …”

“…In this example, there is a nonlinear relationship between the uncertain input parameters and the corresponding cost-effectiveness of the typhoid vaccination program, which is due in part to the use of a dynamic transmission model. 8 …”